Alphabetical Index of Articles by Appendix Cancer, Colorectal Cancer and Pseudomyxoma Peritonei Treatment Specialists
Click here for names and contact info for surgeons and specialists.
We provide the following listing of abstracts and articles, published by, and/or written about the world's most experienced international surgeons and specialists in the treatment and research of Pseudomyxoma Peritonei, and Appendix Cancer. The full titles of some abstracts have been abbreviated due to space limitations.
Alpha listings by surname:
Articles by Dr Syed Ahmad, USA
Title: VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.
Abstract
BACKGROUND: High levels of vascular endothelial growth factor (VEGF) in ovarian cancer metastases are associated with a worse prognosis in patients treated with chemotherapy. VEGF-directed therapy improves survival for those with metastatic colorectal cancer. Patients with mucinous adenocarcinomas metastatic to the peritoneal surfaces can be treated with cytoreductive surgery, and both tumor grade and cytoreduction status are prognostic. We hypothesized that angiogenic indices may be prognostic in patients undergoing cytoreductive surgery for mucinous adenocarcinoma of the appendix and colon.
METHODS: Cytoreductive cases from a 5-year period from the University of Cincinnati peritoneal malignancy database were reviewed. CD 34 counts (blood vessels) and VEGF expression was evaluated by means of immunohistochemistry on specimens from patients undergoing cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP) for mucinous adenocarcinoma.
RESULTS: A total of 26 males and 9 females, with a mean age of 50 years, underwent cytoreductive surgery and IPHP for mucinous adenocarcinoma of appendiceal (n = 32) or colonic (n = 3) origin. With a mean follow-up of 18 months (range 1-63 months), 23 had disease recurrence and 12 were alive without recurrence. The mean survival was 19 months (range 1-63 months). CD34 counts did not correlate with recurrence or survival; however, average VEGF counts correlated with survival (P = 0.017), and, for patients with recurrence, this correlation was stronger (P = 0.002).
CONCLUSIONS: These results suggest that markers of tumor angiogenesis may predict survival in patients with peritoneal surface metastases from mucinous adenocarcinoma. These findings provoke the hypothesis that antiangiogenic therapies may be effective in patients with this devastating disease.
Source:Ann Surg Oncol. 2008 Mar;15(3):738-44. Epub 2007 Nov 28.
Current concepts in the surgical management of pancreatic cancer
Source: Surg Oncol Clin N Am. 2010 Apr;19(2):335-58. Review.PMID: 20159518
Articles by Dr SA Ahrendt, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgical Oncology, Nov 2008
Abstracts by Dr Dario Baratti, Italy
Pseudomyxoma Peritonei
Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Journal of Clinical Oncology, vol. 30, no. 20, pp. 2449–2456, 2012
Importance of gender in diffuse malignant peritoneal mesothelioma
Annals of Oncology, vol. 23, no. 6, pp. 1494–1498, 2012
Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: A controlled study
Annals of Surgical Oncology, vol. 19, no. 5, pp. 1416–1424, 2012
Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies
Annals of Surgery, vol. 255, no. 2, pp. 348–356, 2012
Erratum: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement (Annals of Surgical Oncology 14 (128-133)DOI: 10.1245/s10434-006-9185-7)
Annals of Surgical Oncology, vol. 18, no. SUPPL. 3, pp. S334–S335, 2011
Erratum: Peritoneal sarcomatosis: Is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? (Annals of Surgical Oncology DOI: 10.1245/S10434-010-1178-X)
Annals of Surgical Oncology, vol. 18, no. SUPPL. 3, pp. S327, 2011
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial
Gynecologic Oncology, vol. 122, no. 2, pp. 215–220, 2011
Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research
Journal of Surgical Oncology, vol. 103, no. 8, pp. 822–831, 2011
Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer
European Journal of Surgical Oncology, vol. 37, no. 1, pp. 4–9, 2011
Peritoneal sarcomatosis: Is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Annals of Surgical Oncology, vol. 17, no. 12, pp. 3220–3228, 2010
Multicystic peritoneal mesothelioma: Outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
European Journal of Surgical Oncology, vol. 36, no. 11, pp. 1047–1053, 2010
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma
European Journal of Cancer, vol. 46, no. 15, pp. 2837–2848, 2010
In reply: Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesothelioma
Annals of Surgical Oncology, vol. 17, no. 6, pp. 1713–1714, 2010
Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
European Journal of Surgical Oncology, vol. 36, no. 5, pp. 463–469, 2010
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection
Tumori, vol. 96, no. 2, pp. 340–344, 2010
Lymph node metastases in diffuse malignant peritoneal mesothelioma
Annals of Surgical Oncology, vol. 17, no. 1, pp. 45–53, 2010
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience
Journal of Clinical Oncology, vol. 27, no. 36, pp. 6237–6242, 2009
Circulating CA125 and diffuse malignant peritoneal mesothelioma
European Journal of Surgical Oncology, vol. 35, no. 11, pp. 1198–1199, 2009
Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies
Journal of Surgical Oncology, vol. 100, no. 4, pp. 321–328, 2009
Pseudomyxoma peritonei: Biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy
Annals of Surgery, vol. 249, no. 2, pp. 243–249, 2009
Articles by Dr David L Bartlett, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Dr David L Bartlett, Dr James Pingpank, Dr Steven Ahrendt
Source: Koch Cancer Treatment Center, UPMC
Profile for Dr David L Bartlett
Source: UPMC
Dr David L Bartlett: Koch Cancer Center
Source: UPMC
Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center
Articles by Dr Jean Bereder, France
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Wim Ceelen, Belgium
Dr Wim P Ceelen treats Pseudomyxoma Peritonei with HIPEC www.surgery.ugent.be
Articles by Dr Marcello Deraco, Italy
Pseudomyxoma PeritoneiBiological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
HIPEC Treatment: Dott. Marcello Deraco: Pseudomyxoma Peritonei and Appendix Cancer
Source: Dott. Marcello Deraco
Articles by Dr D Elias, France
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Jesus Esquivel, USA
Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Limited Peritoneal Surface Malignancies: Feasibility, Morbidity and Outcome in an Early Experience.
Laparoscopic CRS and HIPEC in Patients with Limited PSMs
Source: Esquivel J, Averbach A, Chua TC St. Agnes Hospital, Baltimore, Maryland.
Ann Surg. 2011 Jan 6. [Epub ahead of print]
Abstract
INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being widely used in the treatment of patients with peritoneal surface malignancies. The open procedure has been associated with high grade III and IV morbidity and prolonged hospitalization.
METHODS: Patients with peritoneal surface malignancies and no gross evidence of carcinomatosis on the computed tomographic scan were enrolled to undergo laparoscopic CRS and HIPEC. We aimed to assess the feasibility, safety, and outcome of this procedure. Postoperative complications were reported according to the National Cancer Institute Common Toxicity Criteria.
RESULTS: From October 2008 to January 2010, 14 patients were enrolled into the protocol. Amongst these 14 patients, one patient was found with extensive carcinomatosis at the time of laparoscopy and had no surgical procedure. Thirteen patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3 (23%) were converted to an open procedure. There was one grade 3 morbidity (10%) and one patient (10%) in the laparoscopy group experienced a grade 4 complication, needing a reoperation for an internal hernia. Mean length of hospital stay was 6 days for those completed laparoscopically, 8 days for those converted to an open procedure and 8 days for a matched cohort of patients with an upfront open procedure.
CONCLUSIONS: This initial investigative stage demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic route in selected patients with low-tumor volume and no small bowel involvement mainly from appendiceal malignancies. Longer follow-up and additional studies are required to evaluate its long-term efficacy.
PMID: 21217512 [PubMed - as supplied by publisher]
Learning Curve for CRS and HIPEC
Source: Journal of Surgical Oncology, August 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Physician Profile for Dr Jesus Esquivel
Source: St Agnes Hospital
Dr Jesus Esquivel:St Agnes Hospital
Source: St Agnes Hospital
Articles by Dr Jan Franko, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Click here to read Dr Jan Franko's profile
Articles by Dr Gilly, France
Study of 300+ Patients Treated with CRS and PIC :
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
Articles by Dr Joachim Jaehne, Germany
Cytoreductive Surgery Techniques
Source: Dr Joachim Jaehne, August 2009, Wiley
CRS:Stategies to Reduce Post Op Morbidity and Complications
Source: Dr Joachim Jaehne, April 2009
Articles by Dr Santiago Gonzalez-Moreno, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr Martin Goodman, USA
Dr Martin Goodman at Tufts University provides HIPEC
Source: Tufts University, Boston
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Daniel Labow, USA
Sarpel U, Bonavia AS, Grucela A, Roayaie S, Schwartz ME, Labow DM. Does Anatomic Versus Nonanatomic Resection Affect Recurrence and Survival in Patients Undergoing Surgery for Colorectal Liver Metastasis?. Annals of Surgical Onology 2008;. Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, Schwartz ME. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008; 143(3): 366-374.
Cho CS, Labow DM, Gonen M, Jarnagin WR, D'Angelica M, Blumgart L, DeMatteo RP. Impact of Extent of Hepatic Resection for Metastatic Neuroendocrine Carcinoma. Cancer 2008 Jul 1; 113(1): 126-134.
Labow DM, Buell JF, Yoshida A, Rosen S, Posner MC. Isolated pulmonary recurrence after resection of colorectal hepatic metastases--is resection indicated?. Cancer J 8 2002; 8(4): 342-347.
Kammula US, Buell JF, Labow DM, Rosen S, Millis JM, Posner MC. Surgical management of benign tumors of the liver. Int J Gastrointest Cancer 2001; 30(3): 141-146.
Conlon KC, Labow D, Smith A, Jarnagin W, Coit DG, Merchant N, Brennan MF. A prospective randomized clinical trial of the value of intra-peritoneal drainage following pancreatic resection. Annals of Surgery 2001; 234(4): 487-494.
Kaneda Y, Liu D, Brooks A, Abolhoda A, Labow D, Burt ME, Ginsberg RJ. Toxicity and pharmacokinetics of isolated lung perfusion with cisplatin in rat. Japan Journal of Thoracic and Cardiovascular Surgery 2001; 49(7): 443-448.
Buell JF, Rosen S, Yoshida A, Labow D, Limsrichamrern S, Cronin DC, Bruce DS, Wen M, Michelassi F, Millis JM, Posner MC. Hepatic resection: effective treatment for primary and secondary tumors. Surgery 2000; 128(4): 686-693.
Labow D, Lee S, Ginsberg RJ, Crystal RG, Korst RJ. Adenovirus vector-mediated gene transfer to regional lymph nodes. Human Gene Therapy 2000; 11(5): 759-769.
Labow DM, Brennan MF. Gastric Cancer. In: Bayless , Diehl , editors. Advanced Therapy in Gastroenterology and Liver Disease 5/e. BC Decker Inc;.
Articles by Dr Laura Lambert, USA
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Articles by Dr Edward Levine, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
DPAM and HIPEC Treatment
Source: Wake Forest University
Articles by Dr Brian W Loggie, USA
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Gelatinous Ascites: A Cytohistologic Study of Pseudomyxoma Peritonei in 67 Patients
Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network
Articles by Dr Andrew Lowy, USA
Minimally Invasive Laparoscopic Surgery
Source: UCSD, Dr Andrew Lowy, 2009
Dr Andrew Lowy: Moores Cancer Center
Source: UCSD
Treatment of Pancreatic Cancer
Source: Dr Andrew Lowy UCSD
VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA. Source:Ann Surg Oncol. 2008 Mar;15(3):738-44. Epub 2007 Nov 28.
Articles by Dr Paul Mansfield, USA
Profile for Dr Paul Mansfield
Source: MD Anderson
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Paul Mansfield, ASCO 2008
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Laparoscopic Staging for Gastric Cancer
Source: Dr Paul Mansfield, MDACC, Annals of Surgical Oncology, 2001
Laparoscopy for Surgical Oncology
Source: MDACC
Articles by Dr Brendan J Moran, United Kingdom
Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ.
Pseudomyxoma Peritonei Centre, Basingstoke and North Hampshire Hospital Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, UK.
Abstract
BACKGROUND: Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites, predominantly arising form a perforated tumour of the appendix. This study aimed to assess Health-Related Quality of Life (HRQL) in patients following cytoreductive surgery and intraperitoneal chemotherapy for PMP.
METHODS: Over a one year period, 49 consecutive patients (13 male, 36 females) with a median age of 55 (range 37-81 years) were enrolled. Patients were asked to complete the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire prior to surgery and at one, three, six and twelve months post-operatively.
RESULTS: 26 patients (53%) underwent complete cytoreduction and 20 (42%) patients had major tumour debulking. One patient died from progressive disease three months from surgery and two patients withdrew from the study within 6 months of surgery. Baseline questionnaire compliance was 100 per cent and remained high (overall 98% of eligible patients) during follow up. Grade III/IV morbidity occurred in 4 patients (9%). Patients undergoing both complete cytoreduction and major tumour debulking reported a clinically significant improvement in emotional well-being, appetite and global HRQL at 1 year following surgery.
CONCLUSION: Despite the high morbidity associated with cytoreductive surgery and intraperitoneal chemotherapy, an improvement in quality of life at 1 year following the procedure was seen following both complete cytoreduction and major tumour debulking. Longer term assessment is required to demonstrate the durability of this enhancement.
RS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007
Articles by Prof David L Morris, Australia
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris, 2009
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience.
This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
In vivo model for Pseudomyxoma Peritonei research
Source: Prof David L Morris, Sydney Australia, 2009
Articles by Dr Stefaan Mulier, Belgium
Dr Stefaan Mulier provides HIPEC treatment for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis
Source: Leopold Park Clinic in Brussels
Articles by Dr Herwart Mueller, German
CRS for Senior Patients
Source: Dr Herwart Mueller, Germany
Articles by Dr Garrett M Nash USA
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Articles by Dr Michael B Nicholl, USA
1. Nicholl M, Shilyansky J, Ota D. Management of malignant large bowel obstruction.
Contemp Surg 2002; August: 396-400.
2. Nicholl M, Pitt H, Wolf P, Cooney J, Kalayoglu M, Shilyansky J, Rikkers L. Choledochal
cysts in Western adults: complexities compared to children. J Gastrointest Surg
2004; 8:245-52.
3. Nicholl M, Lodge A, Brown I, Sugg S, Shilyansky J. Restored immune response to an
MHC-II restricted antigen in tumor-bearing hosts after elimination of regulatory T
cells. J Pediatr Surg 2004; 39:941-6.
4. Lodge A, Yu P, Nicholl M, Brown I, Jackson C, Schreiber K, Sugg S, Schreiber H,
Shilyansky J. CD 40 ligation restores cytolytic response and eliminates fibrosarcoma
in the peritoneum of mice lacking CD4+ T cells. Cancer Immunol Immunother 2006;
55:1542-52.
5. Nicholl MB, Bilchik AJ. Radiofrequency ablation of colorectal carcinoma liver
metastases. Curr Colorectal Cancer Rep 2007; 3:99-103.
6. Nicholl MB, Morton DL. Sentinel node biopsy in melanoma: standard of care. Am J
Hematol Oncol 2007; 6:468-471.
7. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer?
Ann Surg Oncol 2008; 15:1-3.
8. Nicholl MB, Bilchik AJ. Thermal ablation of hepatic malignancy: useful but still not
optimal. Eur J Surg Oncol 2008; 34:318-23.
9. Huang SK, Darfler MM, Nicholl MB, You J, Bemis KG, Tegeler TJ, Wang M, Wery J,
Chong KK, Nguyen L, Scolyer RA, Hoon DSB. LC/MS-based quantitative proteomic
analysis of paraffin-embedded archival melanomas reveals potential proteomic
biomarkers associated with metastasis. PLoS ONE 2009;4(2): e4430.
10. Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC, Sim M, Morton DL. Age-
related lymphatic dysfunction in malignant melanoma patients. Ann Surg Oncol.
2009 Jun;16(6):1548-52.
11. Nicholl MB, Wright B, Conway WC, Aarnes-Leong T, Sim M, Faries M. Does
specialized surgical training increase lymph node yield in colon cancer? Am Surg
2009 Oct; 75(10): 887-91.
12. Nicholl MB, Conway WC, Ye X, Bilchik A, Singh G. Should Microwave Energy Be
Preferred to Radiofrequency Energy for Malignant Liver Tumor Ablation? J
Interventional Oncol 2010; 3(1): 12-16.
13. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim M, Singh G. Small Bowel
Adenocarcinoma: Understaged and Undertreated? Ann Surg Oncol 2010;
17(10):2728-32.
14. Nicholl MB, Takeuchi H, Elashoff D, Morton DL, Hoon DSB. Molecular upstaging of
paraffin-embedded sentinel lymph nodes predicts long-term outcome in melanoma
patients. Ann Surg 2011;253(1):116-22.
15. Nguyen T, Kuo C, Nicholl MB, Sim M, Turner RR, Morton DL, Hoon DSB. Down-
regulation of MicroRNA-29c is Associated with Hypermethylation of Tumor-Related
Genes and Disease Outcome in Cutaneous Melanoma. Epigenetics. 2011 Mar 1;6(3).
[Epub ahead of print]
16. Fang J, Nicholl MB. Sirtulin 1 and malignant transformation: Friend or foe? Cancer
Lett. 2011 Mar 15. [Epub ahead of print]
17. Wheeler AA, Dale PS, Nicholl MB. Age influences likelihood of treatment, but not
outcome, in pancreatic cancer. In preparation
18. Macarthur K, Nicholl MB. Principles and innovations in peritoneal surface
malignancy treatment. In preparation.
Articles by Dr Haydee Ojeda-Fournier, USA
Diagnostic Imaging of Pancreatic Cancer
Source: Dr Haydee Ojeda-Fournier, UCSD
Articles by Dr Evan Ong, USA
Greenstein SM, Delrio M, Ong E, Feuerstein D, Schechner R, Kim D, Corey H, Kaskel R, Tellis VA, Moritz ML. Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts. Pediatr Nephrol. 2000; 14 (12):1061-5. Babcock TA, Novak T, Ong E, Jho DH, Helton WS, Espat NJ. Modulation of LPS-stimulated macrophage TNF production by ω-3 fatty acid is associated with differential cyclooxygenase-2 (COX-2) enzyme translation and is independent of interleukin-10 (IL-10). Journal of Surgical Research 2002 Sep; 107 (1):135 Ong E, Helton WS, Espat NJ.Operative Experience of U.S. General Surgery Residents: Liver and Pancreas 1989-2001.Journal of Gastrointestinal Surgery. 2003 Feb;7(2):311 Ong E, Gao XP, Xu N, Predescu D, Rahman A, Broman MT, Jho DH, Malik AB. E. coli Pneumonia Induces CD-18 Independent Airway Neutrophil Transalveolar Migration In the Absence of Increased Lung Vascular Permeability. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2003 Oct;285(4):L879-88 Espat NJ, Ong E, Helton WS, Nyhus LM. 1990-2001 U.S. General Surgery Chief Resident Gastric Surgery operative Experience: Analysis of Paradigm Shift. Journal of Gastrointestinal Surgery. 2004 May-Jun;8(4):471-8 Ong E,Gao XP, Predescu D, Broman M, Malik AB. Phosphatidylinositol 3-Kinase Regulation of Neutrophil Extravasation: Role in Lung Inflammation. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2005 December; 289 (6): L1094-103. Ong E, Jho D, Helton WS, Espat NJ. Surgisis®-assisted Delayed Repair of a Complex Bile Duct Injury after Laparoscopic Cholecystectomy. Journal of Gastrointestinal Surgery. 2006 February; 10(2): 202-6. Sharif S, Broman M, Babcock T, Ong E, Jho D, Rudnicki M, Helton WS, Espat NJ. A Priori Dietary {Omega}-3 Lipid Supplementation Results in Local Pancreatic Macrophage and Pulmonary Inflammatory Response Attenuation in a Model of Experimental Acute Edematous Pancreatitis (AEP). Journal of Parenteral and Enteral Nutrition. 2006 July-August; 30(4): 271-6. Jho DH, Jho DJ, Chejfec G, Ahn M, Ong E, Espat NJ. Primary biliary B-cell lymphoma of the cystic duct causing obstructive jaundice. The American Surgeon. 2007 May; 73(5): 508-10. Ong EAlassas M, Bullard Dunn KM, Rajput A. Colorectal Cancer Surgery in the Elderly: Acceptable Morbidity? American Journal of Surgery. 2008 Mar; 195(3):344-8; discussion 348. Brovkovych V, Gao XP, Ong E,Brovkovych S, Brennan ML, Su X, Hazen SL, Malik AB, Skidgel RA. Augmented iNOS Expression and Increased NO Production Reduce Sepsis-Induced Lung Injury and Mortality in Myeloperoxidase-Null Mice. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2008 Jul;295(1):L96-103. Ong E, Alassas M, Bogner PN, Bullard Dunn KM, Chey WY, Gibbs J. Total Gastrectomy for Gastric Dysplasia in a patient with Attenuated Familial Adenomatous Polyposis Syndrome. The Journal of Clinical Oncology 2008 Jul 20;26(21):3641-2.
Articles by Dr Gloria Ortega-Perez, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr James Pingpank, USA
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Articles by Prof Pompiliu Piso, Germany
Peritoneal Carcinomatosis Treatment (Study) with Tumor Honing Peptides
Source: Dept of Radiology, Germany 2009
Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
HIPEC Study with laboratory rats
Source: Deutscher Krebskongress, 2004
Articles by Dr B Ronnett, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Articles by Dr Armando Sardi, USA
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Published abstracts by Dr Armando Sardi
Source: Mercy Medical Center
Steps to Prepare for SurgerySource: Mercy Medical Center
Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center
Profile for Dr Armando Sardi
Source: Mercy Medical Center
Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
Source:J Am Coll Surg. 2009 Sep;209(3):308-12. Epub 2009 Jul 9.PMID: 19717034
Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Source: Ann Surg Oncol. 2008 May;15(5):1414-23. Epub 2008 Feb 26.PMID: 18299935
Articles by Dr Perry Shen, USA
Dr Perry Shen at WFU provides HIPEC
Source: Wake Forest University
Articles by Dr Paul H Sugarbaker, USA
Surgical Responsibilities in the Management of Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, June 2010, Pub Med
Mesenteric Cyst resulting in Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2010
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Epithelial appendiceal neoplasms (abstract with availability to purchase article in full)
Source: The Cancer Journal, 2009
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Management of mucinous urachal neoplasm presenting as Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2008
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Cytoreductive Surgery (includes graphic illustrations) Source: Dr Paul H Sugarbaker
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Appendix Cancer Prognosis
Source: Dr Paul H Sugarbaker, Washington Hospital Center
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul H Sugarbaker, 2005
Atlas of Appendix Cancer(includes graphic illustrations)
Source: Dr Paul H Sugarbaker
Articles referring to Dr Paul Sugarbaker and his patients
Source: PMP Pals' Network
Articles by Dr Jeffrey Sussman, USA
VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA.Division of Surgical Oncology, Department of Surgery, University of Cincinnati Medical Center, 234 Goodman St., ML #0772, Cincinnati, Ohio 45219, USA. Source:Ann Surg Oncol. 2008 Mar;15(3):738-44. Epub 2007 Nov 28.
Articles by Dr Vicktor J Verwaal, Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Cytoreduction and HIPEC Treatment for Appendix Cancer and Pseudomyxoma Peritonei (pdf)
Source: Netherlands Cancer Institute, Prof VJ Verwaal, 2006
Articles by Dr Tristan Yan, Australia
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Articles by Dr H Zeh, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr F Zoetmulder, Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
This webpage is sponsored by "Pal" Patricia Egan Myers
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Updated 08.12.12
Copyright © 2012 by the PMP Pals' Network